`CA CANCER J OLIN BOUI, SFUiy-ss
`
`CancerStatistics, 2000
`
`
`Robert T. Greenlee, MPH, Taylor Murray, Sherry Bolden, Phyllis A. Wingo, PhD, MS
`
`Abstract
`
`Introduction
`
`Canceris an important public health con-
`cern in the United States and around the
`world. To provide an up-to-date perspec-
`tive on the occurrence of cancer, the
`American Cancer Society presents an
`overview of cancerfrequency, incidence,
`mortality, and survival statistics for the
`year 2000.
`
`The Surveillance Research Programof the
`American Cancer Society's Department of
`Epidemiology and Surveillance Research
`reports its annual compilation ofestimated
`cancerincidence, mortality, and survival
`data for the United States in the year 2000.
`After 70 years of increases,
`the recorded
`numberof total cancer deaths among men
`in the US declined for the first time from
`1996 to 1997. This decrease in overall
`male mortality ts the result ofrecent down-
`turns in lung and bronchus cancer deaths,
`prostate cancer deaths, and colon and rec-
`tum cancer deaths.
`Despite decreasing numbers of
`deaths from female breast cancer and
`colon and rectum cancer, mortality asso-
`ciated with lung and bronchus cancer
`among women continues fo increase.
`Lung cancer is expected to account for
`25% of all female cancer deaths in 2000.
`This report also includes a summary
`of global cancer mortality rates using data
`from the World Health Organization.
`(CA Cancer J Clin 2000,;50:7-33.)
`
`Methods
`ESTIMATED NEW CANCER CASES
`Because the US does not have a nation-
`wide cancerregistry, the exact numberof
`new cases of cancer diagnosed each year
`in the US and in individual states is not
`known. Consequently, wefirst estimated
`the numberof new cancercases occurring
`annually in the US from 1979 through
`1996 using population data reported by
`the US Bureauof the Census and age-spe-
`cific cancer incidence rates collected by
`the National Cancer Institute’s Surveil-
`lance, Epidemiology, and End Results
`(SEER)program.' Wefitted these annual
`cancer case estimates to an autoregressive
`Mr. Greenlee is an Epidemiolcgist with the
`quadratic model to forecast the number of
`Surveillance Research Program, Department of
`cancercases expected to be diagnosed in
`Epidemiology and Surveillance, American Cancer
`the USin the year 2000 (Table 1, Fig. 1)?
`Society, Atlanta, GA.
`Between 1987 and 1992, the inci-
`Mr. Murray is Manager, Surveillance Data Systems,
`dence rate of prostate cancer increased
`with the Surveillance Research Program, Depart-
`ment of Epidemiology and Surveillance, American
`85%, followed by a decline of 29% be-
`Cancer Society, Atlanta, GA.
`tween 1992 and 19962 The sharp in-
`Ms. Bolden is Manager, Surveillance Information
`crease in incidence followed by the de-
`Services, with the Surveillance Research Program,
`cline in recent years probably reflects
`Department of Epidemiology and Surveillance,
`extensive use of prostate-specific anti-
`American CancerSociety, Atlanta, GA.
`gen (PSA) screening in a previously un-
`Dr. Wingo is Director of theSurveillance Research
`Program, Department of Epidemiology
`and
`screened population and the subsequent
`Surveillance, American Cancer Society, Atlanta, GA.
`increase in diagnosesat an early stage.*
`The authors thank Cheryll Cardinez, Marlo Corrao,
`We
`assumed that
`the number of
`April Harris, Elyse Luke, and Kate O’Brien for
`prostate cancer cases would approxi-
`their assistance in preparation of this manuscript.
`mate the rates observed prior to wide-
`This article is also availableonline at http://www.
`spread use of PSA screening, and there-
`ca-journal.org.
`
`
`VOL, 50 NO, 1 JANUARY/FEBRUARY 2000:
`
`AstraZeneca Exhibit 2008 p. 1
`InnoPharma Licensing LLC v. AstraZeneca AB
`IPR2017-00904
`Fresenius-Kabi USA LLC v. AstraZeneca AB
`IPR2017-01910
`
`

`

`cancer are expected to be diagnosed.
`Among women, the three most com-
`monly diagnosed cancers are expected to
`be cancers of
`the breast,
`lung and
`bronchus, and colon and rectum (Fig. 1).
`Cancers occurring at these sites are ex-
`pected to account for over 50% of new
`cancer cases in women. Breast cancer
`alone is expected to account for 182,800
`new cancer cases (30% ) in 2000.
`TRENDS IN CANCER INCIDENCE
`
`usedfor the total US (Table 4)?
`OTHER STATISTICS
`
`Mortality statistics for the leading causes
`of death (Tables 6, 7, and 12), the leading
`causes of death from cancer (Tables8, 9),
`and cancer mortality rates from 1930 to
`1996 (Figs. 5, 6) were obtained using data
`from the National Center for Health Sta-
`tistics.° Incidence rates (Table 10, Figs.3,
`4), the probability of developing cancer
`(Table 5), and five-year relative survival
`rates (Tables 11, 13; Figs. 7, 8) were ob-
`tained from the SEER program2° We
`computed global cancer mortality rates
`(Table 14) using data compiled by the
`World Health Organization.’ We includ-
`ed data from countries that have: 1) sub-
`mitted data for at least one of the years
`between 1994 and 1997 using codes from
`the ninth or tenth revision of the Interna-
`tional Classification of Diseases; 2) popu-
`lations of 500,000 or more; 3) death
`
`
`
`Forall sites combined, SEER cancerinci-
`dence rates appeared to peak in 1992 and
`decreased an average of -2.2% per year
`from 1992 to 1996. Similar declines have
`been seen recently for specific leading
`cancersites (Figs.3 and 4).
`Breast cancer incidence rates have
`remained approximately level during the
`1990s; however, they appear to be de-
`creasing in younger women. Decreases in
`colon and rectum cancer incidence rates
`
`CA—A CANCER JOURNAL FOR CLINICIANS
`
`AstraZeneca Exhibit 2008p. 2
`
`

`

`lung and bronchus, prostate, and colon
`and rectum (Fig. 2).
`Among women, cancers of the lung
`and bronchus, breast, and colon and rec-
`tum are expected to account for more than
`halfofall cancer deaths in 2000 (Fig. 2). In
`1987, lung cancer surpassed breast cancer
`as the leading cause of cancer death in
`women and is expected to account for
`25% of all female cancer deaths in 2000.
`
`TRENDS IN THE RECORDED NUMBER OF
`CANCER DEATHS
`
`and 6).” Significant decreases have been
`seen among both males and females,per-
`sons younger than 65 years of age, and
`among whites, blacks, and Hispanics.
`Breast cancer death rates in females
`decreased an average of -1.8% per year
`between 1990 and 1996; decreases were
`more pronounced among white women
`and among younger women. During the
`period from 1990 to 1996, colon and rec-
`tum cancer death rates decreasedsignifi-
`cantly, on average -1.7% per year.
`Similar to trendsin incidence,signifi-
`cant decreases in death rates for lung and
`bronchus cancer have occurred only
`among males (on average -1.6% per year
`between 1990 and 1996); rates amongfe-
`males recently have begun to slow and
`appearto be stabilizing. Prostate cancer
`death rates decreased on average -1.6%
`per year during the period between 1990
`and 1996.
`
`Following more than 70 years of increas-
`es, the recorded number of total cancer
`deaths among men in the UShas declined
`for the first time, from a peak of 281,898
`in 1996 to 281,110 in 1997. This promis-
`ing change results from recent downturns
`in each of the top three causes of cancer
`death among men. Lung and bronchus
`cancer deaths among men declined from
`a peak of 92,493 in 1993 to 91,278 in 1997.
`
`
`VOL. 50 NO. 1 JANUARY/FEBRUARY 2000
`
`AstraZeneca Exhibit 2008p. 3
`
`

`

`tracking trends over time. These estimates
`Blacks are about 33% more likely
`to die of cancer than are whites, and
`may vary considerably from year to year,
`particularly for rare cancers andforstates
`more than twice as likely to die of cancer
`with smaller populations. We therefore
`as are Asian/Pacific Islanders, American
`Indians, and Hispanics. Between 1990
`discourage the use of these estimates to
`track year-to-year changes in cancer oc-
`and 1996, mortality rates decreased sig-
`currence and death. The recorded num-
`nificantly among whites
`(-0.5% per
`ber of cancer deaths and cancer death
`year), blacks (-0.9% per year), and His-
`rates from the National Center for Health
`panics (-0.6% per year); remainedrela-
`Statistics, and SEER cancer incidence
`tively stable among Asian/Pacific Is-
`rates are generally more informative sta-
`landers; and may be increasing among
`American Indians.
`tistics for the purpose of tracking cancer
`trends. For example, breast cancer inci-
`Black womenare morelikely to die
`of breast (see article by Dignam in thisis-
`dence rates increased about 1% per year
`between 1979 and 1982,increased 4% per
`sue of CA, page 50) and colon and rectum
`year between 1982 and 1987, and were ap-
`cancers than are women of any other
`proximately constant between 1987 and
`racial or ethnic group, and they have ap-
`1996. Despite the stabilization of inci-
`proximately the same lung and bronchus
`cancer death rate as white women. As
`dence rates during the latter time period,
`the estimates of new breast cancer cases
`was seen with incidence rates, black men
`increased between 1988 and 1996.
`have the highest mortality rates of colon
`Ourestimates are based on the most
`and rectum,
`lung and bronchus, and
`prostate cancers.?
`currently available cancer mortality and
`
`
`10
`
`CA—A CANCER JOURNAL FOR CLINICIANS
`
`AstraZeneca Exhibit 2008 p. 4
`
`

`

`
`
`ANNOUNCING...
`Continuing Medical Education in CA—A Cancer Journal for Clinicians
`
`The American Cancer Society is pleased to announce that a Continuing Medical
`Education activity will be included in each upcoming issue of CA—A Cancer Journal for
`Clinicians.
`
`When?
`
`What?
`
`Starting March/April 2000!
`
`AMA PRA category 1 CME credits or AAFP Elective hours. Topics to
`include management of cancer pain; malignant melanoma; new treatments for
`smoking cessation; lymphedema, and mind-body integration.
`
`
`for Continuing Medical Education to sponsor continuing medical education
`
`
`Save each issue of CA. Review the article designated for CME credit. Complete
`the accompanying CME quiz and program evaluation. Submit by fax or mail
`for CME credit, according to instructions.
`
`The American Cancer Society, Inc., is accredited by the Accreditation Council
`
`for physicians.
`
`
`
`VOL. 50 NO. 1 JANUARY/FEBRUARY 2000
`
`AstraZeneca Exhibit 2008 p. 5
`
`

`

`
`
`
`23,100
`Ovary
`3,400
`Vulva
`2,100
`Vagina & other genital, female
`180,400
`180,400
`Prostate
`6,900
`6,900
`Testis
`1,100
`1,100
`Penis & other genital, male
`58,600
`86,700
`Urinary system
`38,300
`53,200
`Urinary bladder
`18,800
`31,200
`Kidney & renal pelvis
`1,500.
`2,300
`Ureter & other urinary organs
`1,200
`2,200
`Eye & orbit
`9,500
`16,500
`Brain & other nervous system
`5,600
`20,200
`Endocrine system
`4,700
`18,400
`Thyroid
`900
`1,800
`Other endocrine
`35,900
`62,300
`Lymphoma
`4,200
`7,400
`Hodgkin’s disease
`31,700
`54,900
`Non-Hodgkin's lymphoma
`7,300
`13,600
`Multiple myeloma
`16,900
`30,800
`Leukemia
`1,800
`3,200
`Acute lymphocytic leukemia
`4,600
`8,100
`Chronic lymphocytic leukemia
`4,800
`9,700
`Acute myeloid leukemia
`2,600
`4,400
`Chronic myeloid leukemia
`3,100
`5,400
`Other leukemia
`15,700
`34,000
`Other & unspecified primary sites
`*Excludes basal and squamouscell skin cancers andin situ carcinomas except urinary bladder.
`
`
`23,100
`3,400
`2,100
`
`28,100
`14,900
`12,400
`800
`1,000
`7,000
`14,600
`13,700
`900
`26,400
`3,200
`23,200
`6,300
`13,900
`1,400
`3,500
`4,900
`1,800
`2,300
`18,300
`
`CA—A CANCER JOURNAL FOR CLINICIANS
`
`AstraZeneca Exhibit 2008 p. 6
`
`

`

`
`
`
`
`14,000
`800
`600
`
`8,900
`4,100
`4,600
`200.
`100
`5,900
`1,100
`700
`400
`13,100
`700
`12,400
`5,400
`9,600
`600
`2,000
`3,200
`1,000
`2,800
`18,100
`
`Ovary
`Vulva
`Vagina & other genital, female
`Prostate
`Testis
`Penis & other genital, male
`Urinary system
`Urinary bladder
`Kidney & renal pelvis
`Ureter & other urinary organs
`Eye & orbit
`Brain & other nervous system
`Endocrine system
`Thyroid
`Other endocrine
`Lymphoma
`Hodgkin's disease
`Non-Hodgkin's lymphoma
`Multiple myeloma
`Leukemia
`Acute lymphocytic leukemia
`Chronic lymphocytic leukemia
`Acute myeloid leukemia
`Chronic myeloid leukemia
`Other leukemia
`Other & unspecified primary sites
`*Excludes in situ carcinomas excepturinary bladder.
`
`
`14,000
`800
`600
`31,900
`300
`300
`24,600
`12,200
`11,900
`500
`200
`13,000
`2,100
`1,200
`900
`27,500
`1,400
`26,100
`11,200
`21,700
`1,300
`4,800
`7,100
`2,300
`6,200
`36,600
`
`31,900
`300
`300
`15,700
`8,100
`7,300
`300
`100
`7,100
`1,000
`500
`500
`14,400
`700
`13,700
`5,800
`12,100
`700
`2,800
`3,900
`1,300
`3,400
`18,500
`
`VOL. 50 NO. 1 JANUARY/FEBRUARY2000
`
`13
`
`AstraZeneca Exhibit 2008 p. 7
`
`

`

`
`
`
`
` orth Dakota
`
`300
`700
`100
`300
`200
`700
`100
`600
`=
`700
`5,500
`lew Hampshire}
`
`
`lew Jersey 40,000|6,400 400 4600 1,500 4,800 1,700 1,900 1,000 5,600 2,100
`
`
`
`
`
`
`
`
`New Mexico
`6,600
`1,000
`100
`700
`200
`700
`300
`300
`200
`=1,200
`200
`
`
`lew York 81,500|13,700 1,000 9,200 3,200 9800 2,600 3,800 1,900 11,800 4,100
`
`
`
`
`
`
`
`
`
`
`North Carolina} 35,700|5,200 400 3,700 1,100 5,200 1,300 1400 900 5300 1,400
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3,000 100=100500 = 400 100 300 100 500 100
`
`
`Ohio 56,100|8,600 600 6200 2000 7,800 1,900 2,700 1,500 7,800 2,500
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Oklahoma 16,100|2,400 200=1,700 300=.2,500 ©6500=2,100700 700 700
`
`
`Oregon 15,800|2,200 100 1,600 400 2,200 700 700 400 2,700 700
`
`
`
`
`
`
`
`
`
`Pennsylvania|66,600/10,500 600 7,800 2200 8600 2,400 3,000 1,700 10,000 3,100
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`RhodeIsland 300=1005,400 800 100 600 100 800 200 700 300
`
`
`
`
`
`
`
`
`South Carolina) 18,000|2,600 200=1,900 500=.2.500 =©500=.2,900500 700 800
`
`South Dakota|3,500 400 a 400 100 400 200 200 100 600 100
`
`
`
`
`
`
`
`
`
`
`
`ennessee 27,300|3,800 400 2,900 600 4,200 1,300 1,200 700 3,600 900
`
`
`
`
`
`
`
`
`
`
`€xas 76,100|11,500 1,000 8300 2100 10,700 3,400 3,600 2,200 11,300 2.800
`
`
`
`
`
`
`
`
`Utah
`5,100
`900
`100
`600
`200
`400
`400
`300
`100
`1,200
`200
`Vermont
`2,700
`400
`100
`400
`100
`400
`200
`100
` =100
`300
`100
`
`
`Virginia 29,300|4,500 300 2900 1,000 4,000 1,200 1,200 700 4400 1,100
`
`
`
`
`
`
`
`
`
`
`
`Washington 23,600|3,500 200=2,300 600 3,100 1,100 1,100 600 3200 1,000
`
`
`
`
`
`
`
`
`
`
`
`West Virginia|10,500 300=1,6001,400 100 ~=—-1,100 400 400 300 1,300 400
`
`
`
`
`
`
`
`
`Wisconsin 23,600|3,300 200=2,500 700=2,800 1,000 1,200 700 3800 1,200
`
`
`
`
`
`
`
`
`
`
`
`
`
`Wyoming 100=1002,000 300 — 300 100 200 100 400 =
`
`
`
`United Statest [1,220,100)182,800 12,800 130,200 36,100 164,100 47,700 54,900 31,200 180,400 53,200
`
`
`
`
`
`
`
`
`— Estimate is 50 or fewer cases, State case estimates between 51 and 99 were rounded to 100.
`* Excludes basal and squamouscell skin cancers andin situ carcinomas except urinary bladder.
`t State estimates may not add up to United States total due to rounding,
`
`
`
`ey
`
`CA—A CANCER JOURNAL FOR CLINICIANS
`
`AstraZeneca Exhibit 2008p. 8
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`New Hampshire 300=.100181) 2,500 200 100 700 100 100 100 100 _
`
`
`
`
`
`New Jersey
`179
`18,100}
`1,400
`2,000
`500
`800
`4,600
`900
`500
`1,000
`1,000
`500
`
`
`
`
`
`New Mexico 300=:100146) 3,000 200 100 700 100 100 100 200 100
`
`
`
`
`
`
`New York
`169)
`36,900;
`3100
`4000
`900
`1,400
`9,400
`1,800 1,000
`2,200
`2100
`1,100
`
`
`North Carolina 175|16,200} 1,200 1,600 300 600 5,000 700 400 800 900 300
`
`
`
`
`
`
`
`
`
`
`
`North Dakota 155|1,300 100 200 _ 100 300 100 — 100 100 _
`
`
`
`
`
`
`
`
`
`
`
`Ohio 180|25,400) 1,900 2,700 500 1,000 1,400 1,300 600 1,300 1,400 500
`
`
`
`
`
`
`
`
`
`
`
`
`
`Oklahoma 170|7,300 700=.200500 300 2,400 300 200 300 400 100
`
`
`
`
`
`
`
`
`
`
`
`Oregon 700=:100166} 7,100 500 300 2,100 300 200 400 500 100
`
`
`
`
`
`
`
`
`Pennsylvania 177|30,100} 2,300 3.400 700 1,200 8,200 1,400 800 1,500 1,800 600
`
`
`
`
`
`
`
`
`
`
`
`
`
`RhodeIsland 178|2,400 300=100200 100 800 100 100 100 100 100
`
`
`
`
`
`
`
`
`South Carolina 178|8,200 600 800 200 300 2,400 300 200 400 500 200
`
`
`
`
`
`
`
`
`
`South Dakota
`155)
`1,600
`100
`200
`—_—
`100
`400
`100
`—
`100
`100
`—
`
`
`Tennessee 181|12,400 900 1,200 300 400 4,000 600 300 600 600 300
`
`
`
`
`
`
`
`
`
`
`
`Texas 168|34,400) 2,600 3600 1,100 1,400 10,300 1,700 900 1,700 2,000 900
`
`
`
`
`
`
`
`
`
`Utah
`122}
`2,300
`200
`200
`100
`100
`400
`100
`100
`100
`200
`40
`Vermont
`172}
`1,200
`100
`200
`—
`—
`400
`100
`—
`—
`100
`=
`
`
`Virginia 177|13,300) 1,000 1,300 300 500 3,800 600 300 600 800 300
`
`
`
`
`
`
`
`
`
`
`
`Washington 162|10,700 800 1,000 300 500 3,000 500 300 500 600 200
`
`
`
`
`
`
`
`
`
`
`
`
`
`West Virginia 184|4,800 500=100300 200 1,500 200 100 200 200 100
`
`
`
`
`
`
`
`
`Wisconsin 163|10,700 700 1,100 200 500 2,700 600 300 600 700 200
`
`
`
`
`
`
`
`
`
`Wyoming
`187
`900
`100
`100
`—
`—_
`200
`-
`-—
`_
`100
`_
`
`
`United States 170 |552,200|40,800 56,300 13,800 21,700 156,900 26,100 14,000 28,200 31,900 13,000
`
`
`
`
`
`
`— Estimate is 50 ot fewer deaths. State death estimates between 51 and 99 were rounded to 100.
`* Excludesin situ carcinomas except urinary bladder.
`+ Average annual mortality rate between 1992 and 1996, age-adjusted to the 1970 US standard population.
`Source: US Mortality 1992-1996, National Center for Health Statistics, Centers for Disease Control and Prevention 1999,
`Survelllanes, Epidemiology, and End Results Program,Division of Cancer Control and Population Sciences, National Cancer
`Institute.
`t State estimates may not add up to United States total due to rounding.
`
`VOL. 50 NO. 1 JANUARY/FEBRUARY 2000
`
`13
`
`AstraZeneca Exhibit 2008 p. 9
`
`

`

`Lung & Bronchus
`Prostate
`
`31% -
`11%
`
`Colon & Rectum 10%
`
`:
`
`Pancreas
`
`Non-Hodgkin’s Lymphoma
`
`Leukemia
`
`Esophagus
`
`5%
`
`5%
`
`4%
`
`3%
`
`25% Lung & Bronchus
`15% Breast
`
`11% Colon & Rectum
`
`5% Pancreas
`
`5% Ovary
`
`5% Non-Hodgkin’s Lymphoma
`
`4% Leukemia
`
`
`
`Liver & Intrahepatic Bile Duct 2%—Uterine Corpus3%
`
`
`
`10 Leading Sites by Gender, US, 2000
`
`
`
`
`
`Urinary Bladder
`
`Stomach
`
`3%
`
`3%
`
`All Other Sites
`
`22%
`
`2% Brain & Other Nervous System
`
`2% Stomacht
`
`2% Multiple Myelomat
`21% All OtherSites
`
`*Excludes in situ carcinomas excepturinary bladder.
`+These two cancers both received a ranking of 10; they have the same projected numberof deaths and contribute the
`same percentage. Percentages may not total 100% dueto rounding.
`
`6
`
`CAA CANCER JOURNAL FOR CLINICIANS
`
`AstraZeneca Exhibit 2008 p. 10
`
`

`

`litelz(enpeS/9FL
`
`
`
`(81UlL)p9's(62UlI)Z6°E(velUlL)S8'0(62S'Ul1)90°0aleWN}oay»yUO|OQ
`
`(ZiulL)Lbs(QLUl1)s¢'9(g/Ul1)621(Z6S'ZUl1)¥0'0alellsnyouolg9Gun]
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`‘AIBAYJOSNYOATC‘A}NUISU|1a90uIeD|BLIOReN‘sasuaiogUOARINdoYpUle[O.RUODJADLILDJOIOISIAIG‘GBBL-EZG‘wWeIBolgs}iNseypuypue‘ABojolwapidy‘aoueijlaaing:eounog
`
`(2ulL)9s'er(€ul|)S9'ee(ZiUl1)21'S(29UlL)L9"Lale4sauls|IV
`
`
`
`
` (9Ul1)Lesh(2Ul1)69'SL(9UlOBL=(000‘O}UI|Wey}ssa)alea}e\SOld(8Ul1)95°21(GLUl1)889(GzUl1)90'7(GzUl1)Eb'0ayewe-jsbalg
`
`
`(81Ul1)Sg°g(€€Ul|)90'E(6r1Ul1)£9°0(Z76'LULL)So'0ayeula
`(81Ul1)69'S(G2Ul1)86°E(901Ul1)x60(v6g'2Ul1)€0'0ayeula4
`(eulL)LEee(pUl1)£72(LLUlL)€2°6(ZculL)ve'Lajeue4
`yyead0}yg620}096S01Ob6EO}ULI
`
`
`
`(%)(%)(%)(%)
`UUhymelmeeBertramNCLmelicetedCreCome
`
`
`
`
`
`
`
`'966|PULpE6|UdeMjeqpasouBelpsaseoJeoue9UOpasepurejeAejulabeJoBujuuHaqyeJesuedJoaaySsoulJO,
`
`
`
`
`
`‘yeppeiqArunydeoxeSewoUlose9NUSUlpueSiaouUedUps|j|a29SNoWeNbspuejeseqsapnjoxa
`
`
`‘Bulpunos0}enpJualeAInbeaqjouAeweBeyedieday}JoSSJeAU!OY]PUOASHeIS,,Ul1,SUL
`
`
`
`
`
`
`
`:966L-V6G6L‘SM‘4epucesyAq
`
`
`
`9INIASU|JeouRDjeuOHeN‘O'pUOISIaA
`
`
`Ae
`
`VOL. 50 NO. 1 JANUARY/FEBRUARY2000
`
`AstraZeneca Exhibit 2008 p. 11
`
`

`

` 8
`
`
`
`
`“ddd dddddadddddieicmne
`
`w
`FE EEELEES SES EEESESSSESES
`
`Year
`
`
`
`* Rates are per 100,000 population and are age-adjusted to the 1970 US standard population.
`Source: Surveillance, Epidemiology, and End Results Program, 1973-1996,Division of Cancer Control and Population
`Sciences, National CancerInstitute.*
`
`CA—A CANCER JOURNAL FOR CLINICIANS
`
`AstraZeneca Exhibit 2008 p. 12
`
`o2
`
`.
`odost
`& 60-
`
`oa————e—v—/ — —
`
`-
`
`Onnet ie,
`
`SS aa at ry Ot 9 oy Og
`20-
`eS___eee
`
`

`

`
`
`
`
`
`
`Rateper100,000MalePopulation
`
`_
`
`60
`
`40 -
`
`oe
`
`=
`
`“=
`
`-—=
`
`
`
`~
`
`a
`
`——
`
`
`
`
`
`= =
`sm
`ame BZ ee rae
`i
`=
`oS es oe ey os
`
`.
`
`=
`oo Et ay
`
`
`2S et a es ee oe=
`
`eo my =
`
`
`
`* Rates are per 100,000 population and are age-adjusted to the 1970 US standard population.
`Source: Surveillance, Epidemiology, and End Results Program, 1973-1996,Division of Cancer Control and Population
`Sciences, National CancerInstitute.*
`
`
`VOL. 50 NO. 1 JANUARY/FEBRUARY 2000
`
`1g
`
`AstraZeneca Exhibit 2008 p. 13
`
`

`

`
`
`9,
`
`10.
`
`Cirrhosis
`of Liver
`16,260
`
`Nephtitis
`13,191
`
`Homicide
`15,449
`
`Septicemia
`12,741
`
`
`
`
`
`
`6. Pneumonia—Diabetes Heart Heart Cancer HIV
`
`&lnfluenza
`Mellitus
`Diseases
`Diseases
`5,467
`Infection
`39,284
`34,449
`557
`385
`1,918
`
`tf,
`
`8.
`
`Diabetes
`Mellitus
`28,187
`
`Suicide
`24,492
`
`Accidents
`33,681
`
`Cerebral
`Palsy
`241
`
`Alzheimer’s
`Disease
`15,437
`
`Pneumonia
`& Influenza
`215
`
`Pneumonia
`& Influenza
`200
`
`Cerebral
`Palsy
`186
`
`Cirrhosis
`of Liver
`1,149
`
`Cerebro-
`vascular
`Diseases
`878
`
`Cerebro-
`vascular
`Diseases
`878
`Diabetes
`Mellitus
`619
`
`Chronic
`Obstructive
`Pulmonary
`Diseases
`165
`Chronic
`Peripheral
`Obstructive
`Nervous
`Pulmonary
`System
`Diseases
`Diseases
`101
`148
`Source: US Mortality Public Use Data Tape 1997, National Center for Health Statistics, Centers for Disease Control
`and Prevention, 1999.
`
`
`Benign
`Neoplasms
`103
`
`Diabetes
`Mellitus
`842
`
`Cirrhosis
`of Liver
`571
`
`Pheumonia
`& Influenza
`730
`
`Pneumonia
`& Influenza
`505
`
`20
`
`CA—A CANCER JOURNAL FOR CLINICIANS
`
`AstraZeneca Exhibit 2008 p. 14
`
`

`

`
`
`Chronic
`Obstructive
`Pulmonary
`Diseases
`3,372
`Cirrhosis
`of Liver
`2,814
`
`Suicide
`2,405
`
`Pheumonia
` & Influenza
`1,805
`
`Pneumonia
`& Influenza
`13,576
`
`Pneumonia
`& Influenza
`10,443
`
`Accidents
`10,650
`
`Accidents
`7,145
`
`Diabetes
`Mellitus
`7,302
`
`Accidents
`7,163
`
`Diabetes
`Mellitus
`13,453
`
`Alzheimer’s
`Disease
`12,215
`
`Diseases
`of Arteries
`8,289
`
`Cirthosis
`of Liver
`6,461
`
`Diseases
`of Arteries
`5,300
`
`Nephritis
`4,624
`
`Nephritis
`5,599
`
`Accidents
`9,853
`
`Diseases
`of Arteries
`5,044
`
`Atherosclerosis
`8,017
`
`Cerebro-
`vascular
`Diseases
`6,295
`
`HIV
`Infection
`6,109
`
`Diabetes
`Mellitus
`4,921
`
`Chronic
`Obstructive
`Pulmonary
`Diseases
`3,478
`Homicide
`2,963
`
`Alzheimer’s
`Cirrhosis
`Disease
`of Liver
`4,269
`4,663
`
`
`HIV Infection
`1,446
`
`Nephritis
`5,136
`
`Nephritis
`7,530
`
`Source: US Mortality Public Use Data Tape 1997, National Cen‘er for Health Statistics,
`Centers for Disease Control and Prevention, 1999.
`
`
`VOL. 50 NO. 1 JANUARY/FEBRUARY2000
`
`21
`
`AstraZeneca Exhibit 2008 p. 15
`
`

`

`
`
`30,535
`
`27,792
`
`25,331
`
`25,175
`
`22,475
`
`22,396
`
`19,846
`
`16,516
`
`10.2
`
`“7
`
`6.7
`
`8.2
`
`5.2
`
`6.1
`
`13
`
`5.0
`
`1.3
`
`1.2
`
`11
`
`14
`
`1.0
`
`1.0
`
`0.9
`
`0.7
`
`
`
`8
`
`9
`
`10.
`
`11
`
`12
`
`13
`
`14
`
`15
`
`Suicide
`
`Diseases of Arteries
`
`Nephritis
`
`Cirrhosis of Liver
`
`Alzheimer’s Disease
`
`Septicemia
`
`Homicide
`
`—-HIV Infection
`
`
`Other & Ill-defined
`344,079
`14.9
`
`*Age-adjusted to the 1970 US standard population.
`tPercentages may not total 100% due to rounding.
`Source: US Mortality Public Use Data Tape 1997, National Center for Health Statistics, Centers for
`Disease Control and Prevention, 1999.
`
`
`22
`
`CA—A CANCER JOURNAL FOR CLINICIANS
`
`AstraZeneca Exhibit 2008 p. 16
`
`

`

`
`
`Reported Deaths for the Five Leading Cancer Sites
`for Females by Age, US, 1997
`
`All Ages
`< 20
`20-39
`40-59
`60-79
`280
`All Sites
`All Sites
`All Sites
`All Sites
`All Sites
`All Sites
`258,467
`1,009
`6,159
`45,781
`131,274
`74,240
`Lung &
`Leukemia
`Breast
`Breast
`Lung &
`Lung &
`Bronchus
`322
`1,629
`12,093
`Bronchus
`Bronchus
`61,922
`38,488
`12,879
`Breast
`Breast
`Colon &
`41,943
`18,385
`Rectum
`12,046
`Breast
`9,835
`
`Brain &
`ONS
`253
`Soft
`Tissue
`85
`Endocrine
`System
`79
`
`Uterine
`Cervix
`629
`Lung &
`Bronchus
`462
`Leukemia
`462
`
`Lung &
`Bronchus
`10,088
`Colon &
`Rectum
`3,426
`Ovary
`2,801
`
`
`
`
`Colon &
`Rectum
`28,621
`Pancreas
`14,205
`
`Colon &
`Rectum
`12,799
`Pancreas
`1,A37
`
`Pancreas
`5,045
`
`Ovary
`Bones &
`Brain &
`Uterine
`Ovary
`Non-Hodgkin's
`13,507
`Joints
`ONS
`Cervix
`7,207
`Lymphoma
`
`71
`385
`1,803
`3,859
`Note: “All Sites” excludes in situ carcinomas excepturinary bladder.
`ONS = other nervous system.
`Source: US Mortality Public Use Data Tape 1997, National Center for Health Statistics, Centers for Disease
`Control and Prevention, 1999.
`
`
`VOL. 50 NO. 1 JANUARY/FEBRUARY2000
`
`23
`
`AstraZeneca Exhibit 2008 p. 17
`
`

`

`
`
`Total
`Male
`Female
`Breast (Female)
`Colon & Rectum
`Total
`Male
`Female
`Lung & Bronchus
`Total
`Male
`Female
`Prostate
`
`167.5
`208.8
`139.8
`25.
`
`17.4
`21.5
`14.5
`
`49.3
`10.1
`33.8
`23.7
`
`223.4
`308.8
`168.1
`31.4
`
`23.1
`27.8
`20.0
`
`60.5
`100.8
`32.8
`54.8
`
`103.4
`126.2
`83.5
`11.4
`
`10.9
`13.4
`9.0
`
`23.7
`34.9
`14.9
`10.7
`
`
`
`104.0
`123.3
`90.2
`12.3
`
`9.9
`11.0
`8.9
`
`28.8
`40.5
`19.8
`14.3
`
`104.9
`131.8
`86.3
`15.3
`
`10.4
`13.2
`8.4
`
`19.9
`32.0
`11.0
`16.7
`
`Note: Incidence data are from the 11 SEER areas; mortality data are from all states except Connecticut,
`Oklahoma, Louisiana, and New Hampshire.
`*Rates are per 100,000 population and are age-adjusted to the 1970 US standard population.
`tHispanic is not mutually exclusive of white, black, Asian/Pacific Islander, or AmericanIndian.
`Sources: Surveillance, Epidemiology, and End Results Program 1973-1996, Division of Cancer Control and Population
`Sciences, National CancerInstitute® (Incidence); US Mortality 1973-1996, National Center for Health Statistics, Centers for
`Disease Control and Prevention 1999, Surveillance, Epidemiology, and End Results Program, Division of Cancer Control
`and Population Sciences, National CancerInstitute® (Mortality).
`
`
`24
`
`CA—A CANCER JOURNAL FOR CLINICIANS
`
`AstraZeneca Exhibit 2008 p. 18
`
`

`

`
`
`
`
`
`*Survival rates are adjusted for normallife expectancy and are based on follow-up of patients through 1996.
`+The difference in rates between 1974-1976 and 1989-1995is statistically significant (p <0.05).
`+The standard error of the survival rate is between five and 10 percentage points.
`§The standard errorof the survival rate is greater than 10 percentage points
`Source: Surveillance, Epidemiology and End Results Program 1973-1996, Division of Cancer Control and Population
`Sciences, National CancerInstitute,
`
`
`VOL. 50 NO. 1 JANUARY/FEBRUARY2000
`
`23
`
`AstraZeneca Exhibit 2008 p. 19
`
`Oral Cavity & Pharynx
`
`Ovary
`Pancreas
`Prostate
`
`Rectum
`Stomach
`
`Testis
`
`Thyroid
`
`Urinary bladder
`Uterine Cervix
`
`Uterine Corpus
`
`55
`
`37
`3
`68
`
`49
`15
`
`19
`
`92
`
`74
`710
`
`89
`
`55
`
`39
`3
`15
`
`53
`7
`
`92
`
`94
`
`79
`68
`
`83
`
`56
`
`50T
`At
`98t
`
`60T
`19T
`
`96T
`
`9oT
`
`82T
`AT
`
`86t
`
`36
`
`Al
`3
`58
`
`42
`7
`
`31
`
`3g
`5
`66
`
`38
`1g
`
`16
`
`90t
`
`88
`
`48
`64
`
`61
`
`94
`
`58
`61
`
`54
`
`34
`
`Ait
`At
`84t
`
`Sit
`22
`
`88
`
`89
`
`62t
`59
`
`56
`
`53
`
`37
`3
`67
`
`49
`15
`
`79
`
`92
`
`13
`69
`
`88
`
`53
`
`39
`3
`73
`
`52
`18
`
`92
`
`94
`
`78
`67
`
`82
`
`53
`
`50T
`At
`92+
`
`60T
`2iT
`
`95T
`
`95T
`
`8iT
`70
`
`84t
`
`

`

`
`
`
`
`
`SE ye ie os ire
`I
`I
`1980
`1990
`
`I
`
`Note: Due to changesin the ICD coding, numerator information has changed overtime. Rates for cancerof the uterus,
`ovary, lung & bronchus, and colon & rectum are affected by these coding changes.
`* Rates are per 100,000 population and are age-adjusted to the 1970 US standard population.
`+ Uterine cancer death rates are for uterine cervix and uterine corpus combined.
`Source: US Mortality Public Use Data Tapes 1960-1996, US Mortality Volumes 1930-1959, National Center for Health
`Statistics, Centers for Disease Control and Prevention, 1999.
`
`
`26
`
`CA—A CANCER JOURNAL FOR CLINICIANS
`
`AstraZeneca Exhibit 2008 p. 20
`
`20-
`
`oaoaS
`
`[ao
`
`eeeeee
`ese L
`=.
`
`0-|
`1930
`
`I
`1940
`
`I
`1950
`
`I
`1960
`
`I
`1970
`
`Year
`
`

`

`
`
`
`
`
`
`a=
`wo
`cc
`
`20-
`
`
`0-;
`I
`I
`1930
`1940
`1950
`
`ei ins ceo rae
`
`ane
`
`I
`1960
`
`I
`1970
`
`i
`1980
`
`I
`1990
`
`1
`
`Year
`
`Note: Due to changesin the ICD coding, numerator information has changed over time. Rates for canceroftheliver, lung
`& bronchus, and colon & rectum are affected by these coding changes.
`* Rates are per 100,000 population and a’e age-adjusted to the 1970 US standard population.
`Source: US Mortality Public Use Data Tapes 1960-1996, US Mortality Volumes 1930-1959, National Center for Health
`Statistics, Centers for Disease Control and Prevention, 1999.
`
`
`
`VOL, 50 NO, 1 JANUARY/FEBRUARY 2000
`
`oe
`
`AstraZeneca Exhibit 2008p.21
`
`

`

`
`
`60
`40
`60
`40
`Percent
`Percent
`
`
`0
`
`20
`
`80
`
`100
`
`
`Uterine Corpus
`
`Prostate*
`
`Stomach
`
`Urinary Bladder
`
`Uterine Cervix
`
`0
`
`20
`
`80
`
`100
`
`*The rate for local stage represents local and regional stages combined.
`Note: Staging according to SEER summary stage categories rather than the
`American Joint Committee on Cancer (AJCC) staging system. For each site and
`s
`i
`Oy
`i
`j
`i
`is
`race, stage categories do not total 100% because sufficient information is not
`available to assign a stageto all cancer cases.
`Source: Surveillance, Epidemiology, and End Results Program 1973-1996,
`Division of Cancer Control and Population Sciences, National CancerIrstitute.*
`
`
`Localized
`Regional |
`tnt
`
`28
`
`CA—A CANCER JOURNAL FOR CLINICIANS
`
`AstraZeneca Exhibit 2008 p. 22
`
`

`

`
`
`60
`40
`60
`40
`Percent
`Percent
`
`
`0
`
`20
`
`80
`
`100
`
`0
`
`20
`
`80
`
`100
`
`"The standard error is between five and 10 percentagepoints,
`+The standard error is greater than 10 percentage points.
`tThe ratefor local stage represents local and regional stages combined.
`—Statistic could not be calculated.
`Note: Staging according to SEER summary stage categories rather than the American
`Joint Committee on Cancer (AJCC) staging system.
`Source: Surveillance, Epidemiology, end End Results Program 1973-1996, Division of
`Cancer Control and Population Sciences, National CancerInstitute.?
`
`
`al anges a
`Lopallaed =
`atonal —
`Distant
`
`VOL. 50 NO. 1 JANUARY/FEBRUARY 2000
`
`29
`
`AstraZeneca Exhibit 2008 p. 23
`
`
`12
`
`1 S
`
`% fF
`30
`2
`2 !
`3
`
`& F
`
`a 2
`
`|
`8 .
`56 p
`2 L
`
`Prostatet
`
`Stomach
`
`3
`Urinary Bladder
`
`Uterine Cervix
`
`Uterine Corpus
`
`

`

`
`
`
`
`* Age-adjusted to the 1970 US standard population.
`t+ Percentages may not total 100%due to rounding.
`Source: US Mortality Public Use Data Tape 1997, National Center for Health Statistics, Centers for Disease Control
`and Prevention, 1999.
`
`
`
`30
`
`CA—A CANCER JOURNAL FOR CLINICIANS
`
`AstraZeneca Exhibit 2008 p. 24
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`HIV Infection
`
`Benign Neoplasms
`
`Cerebrovascular Diseases
`
`Septicemia
`
`‘Viral Diseases
`
`Anemias
`
`All Others
`
`156
`
`141
`
`132
`
`125
`
`107
`
`103
`
`2,450
`
`0.3
`
`0.3
`
`0.2
`
`0.2
`
`0.2
`
`0.2
`
`1.2
`
`1.0
`
`1.0
`
`0.9
`
`0.8
`
`0.8
`
`18.1
`
`

`

`
`
`
`
`Note: “All sites” excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder.
`* Survival rates are adjusted for normallife expectancy and are based on ‘follow-up of patients through 1996.
`t The difference in rates between 1974-1976 and 1989-1995is statistica ly significant (p<0.05),
`+ The standard error of the survival rate is between five and 10 percentage points,
`Source: Surveillance, Epidemiology, and End Results Program 1973-1996, Division of Cancer Control and Population
`Sciences, National CancerInstitute.*
`
`
`
`VOL. 50 NO. 1 JANUARY/FEBRUARY2000
`
`31
`
`AstraZeneca Exhibit 2008 p. 25
`
`Hodgkin's Disease
`
`Neuroblastoma
`
`Non-Hodgkin's Lymphoma
`
`Soft Tissue
`
`Wilms’ Tumor
`
`78
`
`53
`
`44
`
`61
`
`14
`
`84
`
`54
`
`51
`
`69
`
`78
`
`91
`
`53
`
`61
`
`65
`
`87
`
`90
`
`55
`
`val
`
`16
`
`86
`
`90
`
`59
`
`10
`
`66
`
`91
`
`93
`
`rabe
`
`tT
`
`T1t
`
`93t
`
`

`

`
`
`
`
`QoL)G96(2oo;GetGellGeers(1eeeLfoouelyz(aeeGadzy|Clip(ee)ezfpuejul4S(Lier(osdzol)weve(evoL|@deoGeely}COLL]Geol)(Less(lercL|clotGelez|Wweloss
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` (poesip|G)etW)eoe)Moesel)Cages(eelzie|Gis|rzz|CAeelUz)ov|los)ks(eles|(selezeses|Vel)Gz(Geos|HOO(HEL!ZSrLSe0der)awee@les|Weadoz)Weseioe|GeezUses|Gre(OL)HeloGeo]feqng<(ve(zs|GSse(pro)diesGes)Coz(lelece|()e0z|Geert)Odellweve|W)GL(odes|Ueele(Ge)ezeL(i2est|{Auewues2Queslosez)Ureers)@L99L|G)LiZ)ZorG)eoe|et(Geo|UHeeorZL)S691(reo)Gale(SHeer|(y)eeL(Le)(ez)201]eles(gic)W)ost(err)OLeer)@)bo2|deerUw)ie)etheyy](rzL|Ueleo(lebe|rege(G2)e¢a1dquederZG)tr@)ro|eeselos|Udoe()oleolefpuejel|5wey(dee|B28Geel]+AleBun}-(ioe(joo|Weer(€)89|@)oz@)ooz|Wor§eluojsy5“eeooo|Oreeo9|aseUedee)@)er@)oz|Ceeesr)@)esCos)Wirt(eloz|fe)zvel©)eeee|Soyqndeyyoaz9:uves@dov|Geze )ez9|LOO)riz)Glez(eve)Ge.(LoseOller]©)esL|(L922)OSLG)rez|)oL(ede)CL)oorL(L)o'eZLSpewusgZz(ess|dozG)¥99]U2ez)Geer]CNezOrel)@det&)e6|(Odezor@)z902(eerlogo])eoe()o¢8)(sel)@)rez)@rer@)eve|(Liye(boos@)yeeldezeSjaeis|6(elo's(rz)Case(seliuz)Ceozt|@)is2]GeetCNEL)GrzL0(GreL|GSbolGe)L221
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`(se)z@(eelee|GHS6(Ubls|@o8|Erizy(iyO9|Gyo(selez|(izeWadery|wea(Woe@)ro|€rze(ovo|(ret(lelgz|(LoeGeese}G)osL|GeeL)GHee(oeoz|er(@dier|(eeee(2)r9q1Feleqsny(raezl|or(eeloz]OEeolGALOr)GEOL)(Le0z)HH2zCiriz|ALL(NO9)Cee(LeoLoLfeLusnylollepe)ezLeleeeL|Gree(selez|(Grsz9(pr)OZLLSuelleqiezy
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`(eel)(doeHOOS|“Hr9L|OLSie)GeoOro;UeLeee]19901(2)e941Fepeuegleo)G)ev(edez]fozdes©)!99)Gos)(sel)CHELLG@)E2z|EOLWILYHaz86@)ozz#ele019(zeules|(ioe(zo)Geez
`
`
`
`
`
`
`
`
`
`(celos(dev|“NeelgeL)G)zoWier)Coo(eezev|weloe|(eesL)GULLez}Gelso(ider|esos(gz)O'0S1(pewebing
`
`
`
`
`
`
`
`
`@)ze(sey|vel(Nelz|GeyGlee]Weleo(rev)@2ozL|(or)LG|OPES(rey|)GUTL(nEz]Galesler)rz6[bequiojog
`
`
`
`
`
`
`
`
`
`zeG@leo|(hozrey|€eozelyz|lozC€ezs]OzesL|(o0Z|EdrolUdesl|Ereeee}(L)eeol(rz)o'9G1fsayeigpayun
`
`
`
`
`
`
`
`
`
`(else(€)gol(esly9(Gelsoz|GogL|GelZL)G@z9wLesoLZe)sep(eloyze|zz@)eoz)~~zoe)lecWeleze]~~|Wrog|)UrOGeez|aLL(elgz|Welses(62)eer:(ezweep|(ILL(e)eze)(eos|roo(HLZ|
`
`
`
`ayeuia4areayeulsae86euOs«CXIAIO)«=BUOYaieaeajeuiey—aypuaaeajeule4aleap